CAS: 1607799-13-2

Bremelanotide acetate is a synthetic peptide therapeutic, which is derived from the melanocortin receptor agonist class. Its primary source involves chemical synthesis designed to mimic endogenous hormone analogs that target specific receptors in the body. The mode of action of bremelanotide acetate involves activating melanocortin receptors, particularly the MC4 receptor in the central nervous system. This activation leads to modulation of brain pathways involved in sexual arousal and desire. Bremelanotide acetate is principally used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. By enhancing neural signaling in relevant paths, it aims to restore diminished sexual desire. This compound is administered via subcutaneous injection, allowing for rapid absorption and onset of action. Its development is rooted in the complex interplay of neurobiological processes underlying sexual function, and it represents a significant advancement in understanding and managing sexual health disorders.

Bremelanotide is a 7 amino acid peptide that is used to treat hypoactive sexual desire disorder in premenopausal women. This drug is an agonist of many melanocortin receptors. Although, its mechanism is unknown, it is said to increase melanin expression which aids in the regulation of sexual arousal. Bremelanotide acetate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Bremelanotide Acetate (PT-141 Acetate) is an agonist of melanocortin receptor (MCR) .

Stability Hygroscopic Applications Bremelanotide is a melanocortin receptor agonist shown to improve female sexual function in females suffering from sexual dysfunction. References Safarinejad, M. et al.: J. Sex. Med., 50, 887 (2008); Pfaus, J. et al.: J. Sex. Med., 4, 269 (2007);

Bremelanotide Acetate